期刊文献+

布地奈德雾化混悬液雾化吸入治疗急性发作性支气管哮喘的疗效观察 被引量:3

Observation on Efficacy of Budesonide Nebulising Suspension in Aerosol Inhalation in Treatment of Acute Paroxysmal Bronchial Asthma
下载PDF
导出
摘要 目的:探讨布地奈德雾化混悬液雾化吸入治疗急性发作性支气管哮喘的疗效及对白细胞介素(IL)2、IL-4、IL-6、IL-8、IL-12、IL-13、IL-25、肿瘤坏死因子α(TNF-α)水平的影响。方法:选择2014年1月—2017年1月收治的急性发作性支气管哮喘患者280例作为研究对象,按随机数字表法分为观察组和对照组,每组140例。对照组患者给予常规治疗,观察组患者在对照组基础上给予布地奈德雾化混悬液雾化吸入,观察两组患者的治疗效果及治疗前后IL-2、IL-4、IL-6、IL-8、IL-12、IL-13、IL-25和TNF-α水平变化情况。结果:治疗后,观察组患者的总有效率为96.43%(135/140),明显高于对照组的82.86%(116/140),差异有统计学意义(P<0.05);两组患者的IL-2、IL-4、IL-6、IL-8、IL-12、IL-13、IL-25及TNF-α等指标水平均较治疗前明显改善,且观察组患者改善程度明显优于对照组,差异均有统计学意义(P<0.05)。结论:布地奈德雾化混悬液雾化吸入治疗急性发作性支气管哮喘效果较好,可显著改善患者临床症状,调节免疫功能,减轻炎症反应。 OBJECTIVE: To probe into the efficacy of budesonide nebulising suspension in aerosol inhalation in treatment of acute paroxysmal bronchial asthma and the effects on interleukin( IL) 2,IL-4,IL-6,IL-8,IL-12,IL-13,IL-25 and tumor necrosis factor alpha( TNF-α). METHODS: 280 patients with acute onset of bronchial asthma admitted from Jan. 2014 to Jan. 2017 were extracted to be divided into observation group and control group via the random number table,with 140 cases in each. The control group was given conventional treatment,while the observation group additionally received budesonide nebulising suspension in aerosol inhalation based on the control group. The changes of IL-2,IL-4,IL-6,IL-8,IL-12,IL-13,IL-25 and TNF-α level of two groups were observed.RESULTS: After treatment,the total effective rate of observation group was 96. 43%( 135/140),significantly higher than that of control group [82. 86%( 116/140) ],with statistically significant difference( P〈0. 05). The IL-2,IL-4,IL-6,IL-8,IL-12,IL-13,IL-25 and TNF-α level of two groups had been improved significantly compared with before treatment,and the observation group was better than the control group,with statistically significant difference( P〈0. 05). CONCLUSIONS: The efficacy of budesonide nebulising suspension in aerosol inhalation in treatment of acute paroxysmal bronchial asthma is remarkable,which can effectively improve patients' clinical symptoms,regulate the immune function and reduce the inflammatory reaction.
出处 《中国医院用药评价与分析》 2017年第8期1049-1051,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 布地奈德混悬液 支气管哮喘 炎性因子 疗效 Budesonide suspension Bronchial asthma Inflammatory factor Efficacy
  • 相关文献

参考文献15

二级参考文献115

  • 1余声华.吸入型糖皮质激素治疗儿童哮喘的临床应用[J].实用儿科临床杂志,2004,19(12):1018-1020. 被引量:36
  • 2钟敏.白三烯受体拮抗剂治疗缓解期老年支气管哮喘的临床疗效观察[J].医学临床研究,2004,21(9):1082-1083. 被引量:10
  • 3邱燕玲,廖万清.吸入糖皮质激素治疗儿童哮喘100例随访研究[J].中国基层医药,2005,12(8):1024-1025. 被引量:13
  • 4华山,魏文,吕敏.肺功能检测在儿童哮喘诊治中的意义[J].小儿急救医学,2005,12(5):370-372. 被引量:15
  • 5Humbert M,Anderss on TL,Buhl R.Budes onide / formoterol for maintenance and reliever therapy in the management of moderate to severe asthma[J].Allergy,2008,63 (12):1567-1580.
  • 6Vaghi A,Berg E,Liljedahl S,et al.In vitro comparis on of nebulisedbudes onide (Pulmicort Res pules) and beclomethas one dip rop ionate(Clenil per Aer os ol)[J].Pulm Pharmacol Ther,2005,18(2):151- 153.
  • 7Rodrfguez-Trigo G, Plaza V, Picado C, et al. Managementaccording to the Global Initiative for Asthma guidelines of patients with near-fatal asthma reduces morbidity and mortality [J]. Arch Bronconeumol, 2008, 44(4) : 192-196.
  • 8Alangari A A. Genomic and non-genomic actions of glucocnrticoids in asthma [J].Ann Thorac Med, 2010,5(3): 133-139.
  • 9Rodrigo G J. Rapid effects of inhaled corticosteroids in acute asthma: an evidence-based evaluation [J]. Chest, 2006, 130 (5) : 1301-1311.
  • 10Wanner A, Horvath G, Brieva J L, et al. Nongenomic actions of glucocorticosteroids on the airway vasculature in asthma [J]. Proc Am Thorac Soc, 2004,1:235-238.

共引文献318

同被引文献40

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部